GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (3)
  • 1
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), ( 2023-09-26), p. OF1-OF11
    Abstract: The optimal application of maintenance PARP inhibitor therapy for ovarian cancer requires accessible, robust, and rapid testing of homologous recombination deficiency (HRD). However, in many countries, access to HRD testing is problematic and the failure rate is high. We developed an academic HRD test to support treatment decision-making. Patients and Methods: Genomic Instability Scar (GIScar) was developed through targeted sequencing of a 127-gene panel to determine HRD status. GIScar was trained from a noninterventional study with 250 prospectively collected ovarian tumor samples. GIScar was validated on 469 DNA tumor samples from the PAOLA-1 trial evaluating maintenance olaparib for newly diagnosed ovarian cancer, and its predictive value was compared with Myriad Genetics MyChoice (MGMC). Results: GIScar showed significant correlation with MGMC HRD classification (kappa statistics: 0.780). From PAOLA-1 samples, more HRD-positive tumors were identified by GIScar (258) than MGMC (242), with a lower proportion of inconclusive results (1% vs. 9%, respectively). The HRs for progression-free survival (PFS) with olaparib versus placebo were 0.45 [95% confidence interval (CI), 0.33–0.62] in GIScar-identified HRD-positive BRCA-mutated tumors, 0.50 (95% CI, 0.31–0.80) in HRD-positive BRCA-wild-type tumors, and 1.02 (95% CI, 0.74–1.40) in HRD-negative tumors. Tumors identified as HRD positive by GIScar but HRD negative by MGMC had better PFS with olaparib (HR, 0.23; 95% CI, 0.07–0.72). Conclusions: GIScar is a valuable diagnostic tool, reliably detecting HRD and predicting sensitivity to olaparib for ovarian cancer. GIScar showed high analytic concordance with MGMC test and fewer inconclusive results. GIScar is easily implemented into diagnostic laboratories with a rapid turnaround.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 77, No. 13_Supplement ( 2017-07-01), p. 3958-3958
    Abstract: Gastric cancer (GC) is the third leading cause of cancer-related death worldwide. With the advent of immunotherapies, there is a need to characterize the phenotype of tumor infiltrating immune cells and co-localized cancer cells. We have shown previously that high density of CD45R0+ T cells is related to better prognosis in Japanese GC. However, the variation of T-cell infiltration in GC is still not understood. We hypothesized that an increased CD8+ T-cell infiltration is related to T-cell activation (high T cell Ki67 proliferation index). Purpose: To establish the frequency of co-occurrence of Ki67+ and CD8+ in T cells and their co-localization with tumor cells and evaluate the relationship with clinicopathological variables including survival. Patients and Methods: Immunohistochemistry for T cells (CD8), proliferation (Ki67), and epithelial cells (CK) was performed on tissue microarrays (TMAs) from 213 GC from the Kanagawa Cancer Centre Hospital (Yokohama, Japan). Stained slides were scanned, quality controlled, and analyzed using Tissue Phenomics (Definiens, Munich, Germany) for cell/nuclei segmentation and automatic co-registration of consecutive sections. The TMA cores were subdivided into tiles of size 64 µm2 to count co-localized positive cells. Average ratio of CD8+ cells and Ki67+ cells per tile/patient was used for statistical analyses. The relationship with pT, pN and histological tumor type was assessed using the Kruskal-Wallis test. Prognostic features were determined by univariate stratification which optimizes Kaplan-Meier p-value using 50 independent pre-validations with 3 folds and ranked by the median pre-validation p-values. P-values & lt; 0.05 were considered significant. Results: 60887 tiles were analyzed in total. Median (range) number of tiles analyzed per patient was 291 (81-345). Median (range) CD8+/Ki67+ ratio was 0.39 (0.01-0.92). Manual inspection of selected image tiles showed that CD8+ cells are rarely Ki67+. Median (range) % of tiles/patient where CD8+Ki67- cells co-localized with Ki67+ tumor cells was 17% (0%-93%). Significant difference of ratio was observed between histological subtypes (p=0.0096). There was no significant relationship between CD8+/Ki67+ and pT or pN. A high CD8+/Ki67+ ratio was related to better survival (p=0.012). Conclusions: This is the first study to suggest that the majority of CD8+ T cells in GC appear to be resting (Ki67-) T cells rejecting our hypothesis that high numbers of intratumoral T cells are due to high intratumoral T cell proliferation. The co-localization of CD8+ T cells and Ki67+ tumor cells seems to be clinically relevant and characterize certain histological phenotypes in GC. However, the potential underlying biological mechanisms of interaction between T cells and tumor cells are currently unknown. Further studies are needed to validate our findings and characterize the interface between tumor and immune cells. Citation Format: Mehmet Yigitsoy, Sophie Earle, Armin Meier, Nathalie Harder, Matthew Hale, Aleksandra Zuraw, Takaki Yoshikawa, Günter Schmidt, Ralf Huss, Heike I. Grabsch. The importance of co-localized resting CD8+ T cells and proliferating tumor cells in gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3958. doi:10.1158/1538-7445.AM2017-3958
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2017
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2016
    In:  Cancer Research Vol. 76, No. 2 ( 2016-01-15), p. 197-205
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 76, No. 2 ( 2016-01-15), p. 197-205
    Abstract: Cancer stem–like cells (CSC) have been proposed to promote cancer progression by initiating tumor growth at distant sites, suggesting that stem-like cell features can support metastatic efficiency. Here, we demonstrate that oncogenic DNp73, a dominant-negative variant of the tumor-suppressor p73, confers cancer cells with enhanced stem-like properties. DNp73 overexpression in noninvasive melanoma and lung cancer cells increased anchorage-independent growth and elevated the expression of the pluripotency factors CD133, Nanog, and Oct4. Conversely, DNp73 depletion in metastatic cells downregulated stemness genes, attenuated sphere formation and reduced the tumor-initiating capability of spheroids in tumor xenograft models. Mechanistic investigations indicated that DNp73 acted by attenuating expression of miR-885-5p, a direct regulator of the IGF1 receptor (IGF1R) responsible for stemness marker expression. Modulating this pathway was sufficient to enhance chemosensitivity, overcoming DNp73-mediated drug resistance. Clinically, we established a correlation between low p73 function and high IGF1R/CD133/Nanog/Oct4 levels in melanoma specimens that associated with reduced patient survival. Our work shows how DNp73 promotes cancer stem–like features and provides a mechanistic rationale to target the DNp73–IGF1R cascade as a therapeutic strategy to eradicate CSC. Cancer Res; 76(2); 197–205. ©2015 AACR.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2016
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...